Get started
Author

Caitlin M. King

Observed name: Caitlin King
Institution: Chordoma Foundation
ORCID: 0000-0001-6305-9331
Observed ORCID: 0000-0001-6305-9331
OpenAlex ID: A5012154783
CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression
2024 · Michael W. Lewis, Caitlin M. King, et al. · Cancer Research · 18
PDF
Enhancer RNA Transcription Is Essential for a Novel CSF1 Enhancer in Triple-Negative Breast Cancer
2022 · Michael W. Lewis, Kamila Wisniewska, et al. · Cancers · 14
PDF
Supplementary Table 6 from CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression
2026 · Michael W. Lewis, Caitlin M. King, et al.
Supplementary Table 5 from CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression
2026 · Michael W. Lewis, Caitlin M. King, et al.
Supplementary Table 1 from CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression
2026 · Michael W. Lewis, Caitlin M. King, et al.
Supplementary Table 4 from CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression
2026 · Michael W. Lewis, Caitlin M. King, et al.
Supplementary Table 2 from CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression
2026 · Michael W. Lewis, Caitlin M. King, et al.
Supplementary Table 3 from CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression
2026 · Michael W. Lewis, Caitlin M. King, et al.
Abstract 252: Targeting replication stress promotes immunogenic cell death in chordoma.
2026 · Nindo Punturi, Arijit Ghosh, et al. · Cancer Research
Pansarcoma Analysis of Cyclin-Dependent Kinase and Cyclin Outlier Gene Expression Highlights CDK7 as a Potential Therapeutic Target in Chordoma
2025 · Daniel S. Lefler, Andrew Elliott, et al. · JCO Precision Oncology
Supplementary Table 6 from CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression
2024 · Michael W. Lewis, Caitlin M. King, et al.
Supplementary Table 3 from CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression
2024 · Michael W. Lewis, Caitlin M. King, et al.
Supplementary Table 5 from CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression
2024 · Michael W. Lewis, Caitlin M. King, et al.
Supplementary Table 2 from CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression
2024 · Michael W. Lewis, Caitlin M. King, et al.
Data from CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression
2024 · Michael W. Lewis, Caitlin M. King, et al.
Supplementary Table 1 from CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression
2024 · Michael W. Lewis, Caitlin M. King, et al.
Supplementary Table 4 from CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression
2024 · Michael W. Lewis, Caitlin M. King, et al.
Supplementary Figures from CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression
2024 · Michael W. Lewis, Caitlin M. King, et al.
Works count: 18
Citation count: 32
H-index: 2
I10-index: 2
Year
Topic
Type